Relay Therapeutics, Inc. (RLAY) financials: revenue, earnings and cash flow
Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$276M, a net margin of -1800.6%; the best year in this period was 2020 with -$52M.
Over the twelve months to September 30, 2026, revenue was $10M and net income -$294M.
Free cash flow was -$236M in fiscal 2025 and positive in 0 of the 7 years shown.
The diluted share count rose 4873% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $15M | $10M | $26M | $1M | $3M | $83M | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$320M | -$303M | -$372M | -$373M | -$299M | -$365M | -$56M | -$84M |
| Net income | -$294M | -$276M | -$338M | -$342M | -$291M | -$364M | -$52M | -$75M |
| EPS (diluted) | $-1.50 | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 | $-5.40 | $-21.82 |
| R&D | $280M | $261M | $319M | $330M | $246M | $173M | $100M | $70M |
| Revenue growth | — | +53.4% | −60.8% | +1749.8% | −54.4% | −96.3% | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$214M | -$235M | -$249M | -$300M | -$229M | -$74M | -$102M | -$66M |
| Capital spending | -$1000 | -$410000 | -$2M | -$4M | -$9M | -$3M | -$2M | -$8M |
| Free cash flow | -$214M | -$236M | -$251M | -$304M | -$239M | -$78M | -$104M | -$74M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — |
| Stock-based pay | $43M | $62M | $94M | $86M | $56M | $48M | $32M | $4M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash | — | $84M | $124M | $144M | $152M | $280M | $448M | $42M |
| Debt | — | $32M | $49M | $53M | $58M | $23M | $24M | $25M |
| Equity | — | $567M | $778M | $752M | $950M | $898M | $763M | -$180M |
| Total assets | — | $621M | $871M | $844M | $1.1B | $1.0B | $800M | $393M |
| Shares (diluted) | 194M | 172M | 143M | 123M | 112M | 95M | 43M | 3M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -3094.6% | -1971.6% | -3722.1% | -1460.1% | -21670.9% | -12040.2% | -67.5% | — |
| Net margin | -2837.0% | -1800.6% | -3374.7% | -1338.7% | -21036.1% | -12012.9% | -63.4% | — |
| FCF margin | -2067.8% | -1536.1% | -2509.5% | -1191.7% | -17273.9% | -2571.1% | -126.3% | — |
| ROIC | — | -39.9% | -35.6% | -36.6% | -23.5% | -31.3% | -5.6% | — |
| ROE | — | -48.8% | -43.4% | -45.5% | -30.6% | -40.5% | -6.9% | 41.7% |
Frequently asked questions
What is Relay Therapeutics’s annual revenue?
$15M in fiscal 2025 and $10M over the twelve months to September 30, 2026.
How much profit does Relay Therapeutics make?
Net income was -$276M in fiscal 2025 (net margin -1800.6%).
Is Relay Therapeutics’s revenue growing?
Yes: revenue rose 53.4% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.